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Abstract
Aims
To evaluate the effect of concomitant dipeptidyl peptidase IV inhibitor (DPPIVi) use on effi-
cacy and safety of insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100)
in people with type 2 diabetes on oral antihyperglycaemic drugs.
Methods
A post hoc patient-level meta-analysis was performed using data from EDITION 2 (basal
insulin [N = 811]) and EDITION 3 (insulin-naïve [N = 878]), multicentre, randomised, open-
label, parallel-group, phase 3a trials of similar design. Endpoints analysed included HbA1c,
hypoglycaemia and adverse events, investigated in subgroups of participants with and with-
out concomitant DPPIVi use.
Results
Of 1689 participants randomised, 107 (13%, Gla-300) and 133 (16%, Gla-100) received
DPPIVi therapy. The least squares mean change in HbA1c (baseline to month 6) was com-
parable between treatment groups, irrespective of DPPIVi use (no evidence of heterogene-
ity of treatment effect across subgroups, p = 0.753), although group sizes were unbalanced.
The cumulative mean number of confirmed (3.9 mmol/L [70 mg/dL]) or severe hypogly-
caemic events, and the risk and annualised rate of such events, were consistently lower for
Gla-300 than Gla-100 during the night (between 00:00 and 05:59 h) or at any time of day (24
h period), irrespective of DPPIVi use. Severe hypoglycaemia occurred in 8/838 and 10/844
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participants in the Gla-300 and Gla-100 groups, respectively, and was not affected by
DPPIVi use. The adverse event profile was similar between treatment groups and DPPIVi
subgroups.
Conclusions
Glycaemic control with Gla-300 was comparable to Gla-100, with less hypoglycaemia during
the night and at any time of day (24 h), irrespective of concomitant DPPIVi use.
Trial registration
ClinicalTrials.gov NCT01499095; NCT01676220
Introduction
Type 2 diabetes is a chronic, progressive disease that requires complex management strategies
[1]. People with type 2 diabetes typically start monotherapy with biguanides (e.g. metformin)
[2]. However, as the disease progresses, most patients will require combination therapy with
one or more oral antihyperglycaemic drugs (OADs), and/or non-insulin injectable antihyper-
glycaemic drugs, as well as basal insulin or more complex insulin regimens, to compensate for
the diminishing insulin secretory capacity [2].
Insulin glargine 300 U/mL (Toujeo1, Sanofi, Paris, France [Gla-300]) is a basal insulin,
approved in many countries, which has a more stable and prolonged pharmacokinetic profile
than insulin glargine 100 U/mL (Lantus1, Sanofi, Paris, France [Gla-100]) [3]. The safety and
efficacy of Gla-300 compared with Gla-100 was investigated in 1689 participants with type 2 dia-
betes receiving concomitant OADs in the EDITION 2 (background therapy basal insulin + OAD)
and EDITION 3 (background therapy OAD only, insulin-naïve) studies [4, 5]. For those receiving
sulphonylureas, use of these medications was stopped prior to randomisation and prohibited dur-
ing both studies. Results from these studies have shown that Gla-300 provides comparable glycae-
mic control to Gla-100 with less hypoglycaemia, over 6 months of treatment [4, 5].
Other than biguanides, which were used by more than 90% of participants, the most com-
mon class of OADs in the EDITION 2 and 3 studies was dipeptidyl peptidase IV inhibitor
(DPPIVi) therapy. DPPIVi therapy is becoming increasingly popular in the treatment of type
2 diabetes because it is associated with a lower risk of hypoglycaemia compared with sulphony-
lureas or glinides [6]. Previous studies of DPPIVi and basal insulin use in patients with type 2
diabetes have shown that this combination therapy leads to improved glycaemic control com-
pared with basal insulin alone without an increase in hypoglycaemia, and with little or no
effect on body weight or insulin dose [7–13].
This post hoc patient-level meta-analysis aimed to assess the combination of DPPIVi ther-
apy with Gla-300, and compared the efficacy and safety of Gla-300 and Gla-100 with or with-
out concomitant DPPIVi use in people with type 2 diabetes in the EDITION 2 and EDITION
3 studies, over 6 months of treatment.
Participants and methods
Study design and participants
EDITION 2 (NCT01499095) and EDITION 3 (NCT01676220) were multicentre, randomised,
open-label, two-arm, parallel group, treat-to-target phase 3a studies forming part of the
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EDITION programme. Full study methods and results for these studies have been published
previously [4, 5]. Both studies enrolled adults18 years of age with type 2 diabetes. In EDI-
TION 2, participants on prior basal insulin42 U/day plus OADs with HbA1c53 to86
mmol/mol (7.0 to10.0%) were enrolled. In EDITION 3, participants who were on OADs
(and insulin-naïve) with HbA1c53 to97 mmol/mol (7.0 to11.0%) were enrolled. In
brief, participants were randomised (1:1) to once-daily subcutaneous injections of Gla-300
(using a modified SoloSTAR1 [EDITION 2] or a modified Tactipen1 [EDITION 3] pen-
injector) or Gla-100 (using a SoloSTAR1 pen-injector), administered at the same time each
evening. Evening was defined as the period from immediately prior to the evening meal until
bedtime. Gla-300 and Gla-100 were titrated to a fasting self-monitored plasma glucose target
of 4.4–5.6 mmol/L (80–100 mg/dL). Appropriate local or national ethics committees approved
the study protocols, and both studies were registered with ClinicalTrials.gov and conducted
according to Good Clinical Practice and the Declaration of Helsinki.
Although EDITION 2 and EDITION 3 were conducted in different populations of people
with type 2 diabetes, the consistent study designs (as described above) and endpoints allowed a
pooled analysis to be performed. For this post hoc analysis of EDITION 2 and 3, the consis-
tency of results was examined across four subgroups of the pooled populations (participants
receiving either Gla-300 or Gla-100, with or without concomitant DPPIVi therapy).
Outcomes
The pooled analysis of the effect of DPPIVi use was carried out for the following endpoints:
change from baseline to month 6 in mean HbA1c (% [NGSP units]), percentage of participants
achieving HbA1c<7.0%; daily basal insulin dose (U/kg) and body weight (kg); percentage of par-
ticipants with1 hypoglycaemic event, hypoglycaemic event rates per participant-year and
cumulative mean number of hypoglycaemic events per participant (during the night [00:00–05:59
h] or at any time of day [24 h]); and adverse events during the 6-month study period. Confirmed
or severe hypoglycaemia combined three American Diabetes Association definitions of hypogly-
caemia [14]: documented symptomatic hypoglycaemia (typical symptoms of hypoglycaemia
accompanied by a measured plasma glucose concentration of3.9 mmol/L [70 mg/dL] or
<3.0 mmol/L [<54 mg/dL]), asymptomatic hypoglycaemia (no symptoms of hypoglycaemia, but
confirmed by a measured plasma glucose concentration of3.9 mmol/L [70 mg/dL] or<3.0
mmol/L [<54 mg/dL]), and severe hypoglycaemia (an event requiring the assistance of another
person to actively administer carbohydrate, glucagon or other resuscitative actions).
Data analysis and statistics
Change in HbA1c from baseline to month 6 was analysed using a mixed model for repeated
measurements approach. The model included fixed categorical effects of treatment group,
visit, treatment-by-visit interaction, randomisation strata of screening HbA1c (<8,8%), and
study, as well as the continuous fixed covariates of baseline HbA1c value and baseline HbA1c
value-by-visit interaction. Homogeneity of treatment effect across the two trials was also
assessed. For hypoglycaemic events, relative risks were analysed using a Cochran–Mantel–
Haenszel method, and rate ratios were analysed using an overdispersed Poisson regression
model. Cumulative mean numbers of hypoglycaemic events per participant were evaluated
using Nelson–Aalen estimates.
A heterogeneity test was performed to assess treatment effect across DPPIVi use sub-
groups and p-values were generated using a subgroup-by-treatment interaction. Differences
between subgroups were considered significant if the subgroup-by-treatment interaction
p-value was<0.05.
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Insulin dose, baseline characteristics, percentage of participants achieving HbA1c <7.0%,
adverse events and body weight were analysed descriptively.
Efficacy endpoints were analysed according to the treatment group assigned at randomisa-
tion and using the modified intention-to-treat (mITT) population, defined as all randomised
participants who received at least one dose of study drug and had both a baseline and at least
one post-baseline assessment. Safety endpoints were analysed according to the treatment actu-
ally received and using the safety population, which included all participants randomised and
exposed to at least one dose of study drug.
Results
Study population
Overall, 1689 participants (the majority of whom were on biguanides [1562, 92%]) were ran-
domised to treatment in the EDITION 2 and EDITION 3 studies. Of these 736/843 (87%) in
the Gla-300 group and 713/846 (84%) in the Gla-100 group did not receive concomitant
DPPIVi therapy; 107 (13%) and 133 (16%) participants, respectively, were receiving DPPIVi
therapy. The mITT population comprised 1670 participants (Gla-300: n = 835 [without
DPPIVi: n = 728 (87%); with DPPIVi: n = 107 (13%)]; Gla-100: n = 835 [without DPPIVi:
n = 702 (84%); with DPPIVi: n = 133 (16%)]).
Baseline characteristics, including concomitant OAD use, are summarised in Table 1. Base-
line characteristics were similar within both the ‘without DPPIVi’ and ‘with DPPIVi’ sub-
groups. The majority of participants on concomitant DPPIVi therapy received sitagliptin
phosphate (77% each in the Gla-300 and Gla-100 groups; Table 2).
Glycaemic response
A comparable decrease in HbA1c was observed in both treatment groups, irrespective of
DPPIVi use (Fig 1). The mean ± standard deviation (SD) HbA1c reduction between baseline
and month 6 was 12 ± 12 mmol/mol (1.1 ± 1.1%) in the Gla-300 without DPPIVi subgroup,
13 ± 11 mmol/mol (1.2 ± 1.0%) in the Gla-300 with DPPIVi subgroup, 12 ± 13 mmol/mol
(1.1 ± 1.2%) in the Gla-100 without DPPIVi subgroup and 12 ± 10 mmol/mol (1.1 ± 0.9%) in
the Gla-100 with DPPIVi subgroup. The least squares mean change from baseline to month 6
was comparable between insulin treatment groups, in participants who did or did not receive
concomitant DPPIVi therapy (no evidence of heterogeneity of treatment effect across sub-
groups, p = 0.753; Fig 1). The study-by-treatment interaction was found to be non-significant.
In those receiving Gla-300, the number of participants achieving HbA1c <7.0% at month 6
was 267 (38.4%) and 50 (50.0%) in the without and with DPPIVi subgroups, respectively. Cor-
responding numbers of Gla-100-treated participants were 248 (37.2%) and 62 (47.0%),
respectively.
Insulin dose
The mean ± SD daily average basal insulin dose increased numerically in both treatment
groups, to 0.78 ± 0.34 U/kg for Gla-300 without DPPIVi, 0.73 ± 0.35 U/kg for Gla-300 with
DPPIVi, 0.71 ± 0.30 U/kg for Gla-100 without DPPIVi and 0.59 ± 0.29 U/kg for Gla-100 with
DPPIVi, at month 6 (S1 Table). The majority of the increase took place in the first 12 weeks of
treatment. In participants who did not receive DPPIVi therapy, the mean (SD) change from
baseline to month 6 in daily average basal insulin dose was 0.36 ± 0.26) U/kg for Gla-300 and
0.27 ± 0.24 U/kg for Gla-100 (S1 Table). Corresponding values in participants who received
DPPIVi were 0.41 ± 0.28 U/kg and 0.23 ± 0.20 U/kg (S1 Table).
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Hypoglycaemia
Confirmed (3.9 mmol/L [70 mg/dL]) or severe hypoglycaemia. The cumulative
mean number of confirmed (3.9 mmol/L [70 mg/dL]) or severe hypoglycaemic events per
participant remained lower with Gla-300 versus Gla-100 over 6 months, both at night (00:00–
05:59 h) and at any time of day (24 h), regardless of DPPIVi use (Fig 2).
Table 1. Baseline demographic and clinical characteristics, by concomitant DPPIVi use (pooled randomised population).
Participants without concomitant DPPIVi use Participants with concomitant DPPIVi use
Gla-300 (N = 736) Gla-100 (N = 713) Gla-300 (N = 107) Gla-100 (N = 133)
Age, years 57.7 ± 9.4 57.4 ± 9.8 60.4 ± 10.2 60.4 ± 9.7
Gender (male), n (%) 379 (51.5) 359 (50.4) 61 (57.0) 80 (60.2)
Racial group, n (%)
Caucasian
Black
Asian/Oriental
Other
643 (87.4)
55 (7.5)
27 (3.7)
11 (1.5)
617 (86.5)
63 (8.8)
26 (3.6)
7 (1.0)
82 (76.6)
9 (8.4)
15 (14.0)
1 (0.9)
104 (78.2)
10 (7.5)
18 (13.5)
1 (0.8)
Body weight, kg 97.2 ± 22.9 96.4 ± 21.3 94.2 ± 22.6 98.3 ± 24.0
BMI, kg/m2 33.9 ± 6.8 33.9 ± 6.2 32.6 ± 6.9 34.2 ± 7.2
Estimated GFR, mL/min/1.73 m2 82.4 ± 20.0 81.8 ± 20.4 76.5 ± 23.8 74.2 ± 19.2
Duration of diabetes, years 11.2 ± 6.7 11.0 ± 6.8 12.1 ± 8.1 11.2 ± 6.4
Duration of basal insulin,† years 6.2 ± 5.4 6.4 ± 5.1 5.2 ± 4.5 5.2 ± 4.3
Prior basal insulin dose,‡ U/kg/day 0.66 ± 0.21 0.69 ± 0.26 0.71 ± 0.29 0.65 ± 0.22
HbA1c
mmol/mol
% (NGSP units)
69 ± 11
8.4 ± 1.0
69 ± 11
8.4 ± 1.0
66 ± 9
8.2 ± 0.9
66 ± 9
8.2 ± 0.8
Concomitant antihyperglycaemic medication use,§ n (%)
Biguanides
GLP-1 receptor agonists
Sulphonylureas¶
Thiazolidinediones
697 (94.7)
22 (3.0)
26 (3.5)
23 (3.1)
676 (94.8)
17 (2.4)
27 (3.8)
25 (3.5)
80 (74.8)
0 (0.0)
2 (1.9)
3 (2.8)
109 (82.0)
1 (0.8)
5 (3.8)
15 (11.3)
Data are pooled from EDITION 2 and EDITION 3, and are presented as mean ± SD unless otherwise indicated
Without DPPIVi use: Gla-300 N = 731, Gla-100 N = 711, with DPPIVi use: Gla-300 N = 107, Gla-100 N = 132
†EDITION 2 study only, without DPPIVi use: Gla-300 N = 372, Gla-100 N = 354, with DPPIVi use: Gla-300 N = 32, Gla-100 N = 53
‡EDITION 2 study only, without DPPIVi use: Gla-300 N = 350, Gla-100 N = 334, with DPPIVi use: Gla-300 N = 29, Gla-100 N = 50
§Participants could be on >1 antihyperglycaemic medication (EDITION 2: use of sulphonylureas prohibited within 2 months prior to screening and during study;
EDITION 3: sulphonylureas, glinides and other OADs not approved for use with insulin were discontinued at baseline)
¶Prior use of sulphonylurea was reported in 275 (33%) of Gla-300-treated participants and 268 (32%) of Gla-100-treated participants; the majority of these participants
(Gla-300: 247/275 [89.8%]; Gla-100: 236/268 [88.1%]) discontinued sulphonylurea use at randomisation as per protocol. BMI, body mass index; DPPIVi, dipeptidyl
peptidase IV inhibitor; GFR, glomerular filtration rate; GLP-1, glucagon-like peptide 1; NGSP, National Glycohemoglobin Standardization Program; OAD, oral
antihyperglycaemic drug
https://doi.org/10.1371/journal.pone.0190579.t001
Table 2. Type of concomitant DPPIVi therapy used (pooled randomised population).
DPPIVi type, n (%) Gla-300
(N = 107)
Gla-100
(N = 133)
Sitagliptin 82 (76.6) 103 (77.4)
Saxagliptin 12 (11.2) 15 (11.3)
Linagliptin 8 (7.5) 5 (3.8)
Vildagliptin 6 (5.6) 10 (7.5)
Data are pooled from EDITION 2 and EDITION 3. DPPIVi, dipeptidyl peptidase IV inhibitor
https://doi.org/10.1371/journal.pone.0190579.t002
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The risk of1 confirmed (3.9 mmol/L [70 mg/dL]) or severe hypoglycaemic event was
consistently lower with Gla-300 than with Gla-100, at night (00:00–05:59 h) and at any time of
day (24 h), regardless of DPPIVi use (no evidence of heterogeneity of treatment effect across
subgroups, p = 0.476 [nocturnal events]; p = 0.950 [events at any time of day]) (S2 Table and
Fig 3). For example, the risk of experiencing1 nocturnal confirmed (3.9 mmol/L [70 mg/
dL]) or severe hypoglycaemic events was reduced by 29% (relative risk 0.71 [95% CI: 0.60 to
0.85]) in the ‘without DPPIVi’ subgroup and by 14% (relative risk 0.86 [95% CI 0.57 to 1.28])
in the ‘with DPPIVi’ subgroup. In the ‘with DPPIVi’ subgroup, the reduction did not achieve
statistical significance as the upper bound of the 95% CI exceeded 1. The risk of experiencing
1 any time of day (24 h) confirmed (3.9 mmol/L [70 mg/dL]) or severe hypoglycaemic
events was reduced by approximately 10% in both the ‘without’ (relative risk 0.90 [95% CI:
0.83 to 0.97] and ‘with’ (relative risk 0.91 [95% CI: 0.75 to 1.10]) DPPIVi subgroups, although
statistical significance was not achieved in the ‘with’ subgroup.
The annualised rate of confirmed (3.9 mmol/L [70 mg/dL]) or severe hypoglycaemic
events at night (00:00–05:59 h) and at any time of day (24 h) was also lower with Gla-300 than
with Gla-100, regardless of DPPIVi use (no evidence of heterogeneity of treatment effect across
subgroups, p = 0.276 [nocturnal events]; p = 0.978 [events at any time of day]) (S2 Table and
Fig 3). The rate of nocturnal confirmed (3.9 mmol/L [70 mg/dL]) or severe hypoglycaemic
events was reduced by 40% in the ‘without DPPIVi’ subgroup (rate ratio 0.60 [95% CI: 0.44 to
0.82]) and by 5% in the ‘with DPPIVi’ subgroup (rate ratio 0.95 [95% CI: 0.45 to 2.03]). Any
time of day (24 h) confirmed (3.9 mmol/L [70 mg/dL]) or severe hypoglycaemic events
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EDITION 3. CI, confidence interval; DPPIVi, dipeptidyl peptidase IV inhibitor; RR, relative risk for participants with1 event or rate ratio for
events per participant-year.
https://doi.org/10.1371/journal.pone.0190579.g003
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rates were reduced by 23% in both DPPIVi subgroups, although the upper bound of the 95%
CI exceeded 1 in the ‘with DPPIVi’ subgroup (S2 Table and Fig 3).
A consistent pattern was observed for the incidence and annualised rate of confirmed or
severe hypoglycaemic events at the stricter <3.0 mmol/L (<54 mg/dL) threshold (S2 Table
and Fig 3). For both nocturnal (00:00–05:59 h) and any time of day (24 h) hypoglycaemic
events there was no evidence of heterogeneity of treatment effect according to DPPIVi sub-
group: p = 0.710 and p = 0.218 (incidence of nocturnal and any time of day [24 h] events,
respectively) and p = 0.906 and 0.949 (rate of nocturnal and any time of day [24 h] events,
respectively). As with the less stringent glucose threshold, individual reductions in risks for the
stricter (<3.0 mmol/L [<54 mg/dL]) threshold achieved statistical significance in the ‘without
DPPIVi’ subgroup and did not achieve significance in the ‘with DPPIV’ subgroup (S2 Table
and Fig 3).
Severe hypoglycaemia. Severe hypoglycaemia occurred in 8/838 (1.0%) participants in
the Gla-300 group (without DPPIVi: 6/731 [0.8%]; with DPPIVi: 2/107 [1.9%]) and 10/844
(1.2%) participants in the Gla-100 group (without DPPIVi: 9/711 [1.3%]; with DPPIVi: 1/133
[0.8%]). The relative risk (95% confidence interval [CI]) for Gla-300 versus Gla-100 was 0.82
(0.33 to 2.00) overall, 0.67 (0.25 to 1.80) for the ‘without DPPIVi’ subgroup and 1.40 (0.29 to
6.62) for the ‘with DPPIVi’ subgroup. The concomitant use of DPPIVi had no impact on the
incidence of severe hypoglycaemia (no evidence of heterogeneity of treatment effect across
subgroups, p = 0.298).
Weight change
In participants not receiving DPPIVi therapy, mean ± SD body weight change was 0.26 ± 3.74
kg and 0.83 ± 3.39 kg in the Gla-300 and Gla-100 group, respectively. In participants receiving
concomitant DPPIVi therapy, mean ± SD body weight change from baseline to month 6 was
0.68 ± 3.63 kg in the Gla-300 group and 0.37 ± 3.46 kg in the Gla-100 group.
Adverse events
The adverse event profile was similar between subgroups, irrespective of concomitant DPPIVi
use (S3 Table).
Discussion
The results of this post hoc patient-level meta-analysis of the EDITION 2 and EDITION 3
studies were consistent with those observed in the individual study populations [4, 5]. The
HbA1c reduction over the 6-month study period was comparable between the Gla-300 and
Gla-100 groups, irrespective of concomitant DPPIVi use. Additionally, Gla-300 was associated
with a lower risk of experiencing1 confirmed (3.9 mmol/L [70 mg/dL]) or severe hypo-
glycaemic event than Gla-100, both at night and at any time of day, regardless of DPPIVi use
(no significant difference between treatments by subgroup interaction: p = 0.476 and 0.950,
respectively). Overall, the results from this analysis suggest that combination therapy with Gla-
300 and DPPIVi is efficacious and well tolerated.
With incretin-based therapies such as DPPIVi becoming increasingly popular in the treat-
ment of type 2 diabetes, it is of clinical importance to assess the efficacy and safety of the com-
bination of DPPIVi therapy with basal insulin. This topic has been addressed in a number of
randomised controlled trials that have evaluated the administration of DPPIVi in previously
DPPIVi-naïve patients with type 2 diabetes who were poorly controlled on basal insulin ther-
apy [8, 10]. However, in contrast to the studies considered in this analysis, the basal insulin
dose was pre-specified to remain stable in most of these studies [8], probably because these
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studies were designed to evaluate the effect of the DPPIVi rather than that of the insulin. Com-
parisons between results from these studies of DPPIVi use and those from the analysis pre-
sented here should therefore be made with caution. The current post hoc analysis adds to the
limited body of evidence in this setting, and is the first study to evaluate combination therapy
with DPPIVi and the recently approved Gla-300. Only one study by Mathieu et al. has investi-
gated the co-administration of sitagliptin (the DPPIVi most commonly used by participants in
the EDITION studies in this analysis) with Gla-100 in a treat-to-target trial in people with type
2 diabetes [9].
Owing to the treat-to-target design of the EDITION trials, HbA1c change from baseline was
comparable with Gla-300 and Gla-100, for both the ‘with DPPIVi’ and ‘without DPPIVi’ sub-
groups. This comparable reduction in HbA1c (LS mean treatment difference 0.01% ‘with
DPPIVi’ and −0.03% ‘without DPPIVi’), accompanied by the lower risk of hypoglycaemia with
Gla-300 versus Gla-100, was associated with a numerically higher daily insulin dose for Gla-
300, regardless of DPPIVi use (note statistical testing was not performed on insulin dose). Dif-
ferences between the DPPIVi use subgroups were seen in Gla-100-treated participants, with
the daily basal insulin dose at month 6 being numerically lower for participants on concomi-
tant DPPIVi therapy compared with those who were not. The results observed in the Gla-100
group are aligned with those of the Mathieu et al. study, in which participants receiving sita-
gliptin required a lower dose of Gla-100 than those receiving placebo [9]. In most other studies
of the co-administration of basal insulin and DPPIVi, the dose of insulin remained essentially
unchanged [7, 8, 11, 12]. Nevertheless, it should be noted that differences in the numbers of
people in the ‘with DPPIVi’ and ‘without DPPIVi’ subgroups (mITT population: with DPPIVi:
n = 240; without DPPIVi: n = 1430) in the current analysis limit interpretation.
As indicated by non-statistically significant treatment-by-subgroup interaction p-values,
the lower risk and lower annualised rate of confirmed (3.9 mmol/L [70 mg/dL]) or severe
hypoglycaemia (nocturnal [00:00–05:59 h, p = 0.476 and p = 0.276; respectively] and at any
time of day [24 h], p = 0.950 and p = 0.978; respectively) with Gla-300 versus Gla-100 seen in
the EDITION 2 and EDITION 3 studies was observed in this analysis irrespective of concomi-
tant DPPIVi use. The cumulative mean number of confirmed (3.9 mmol/L [70 mg/dL]) or
severe hypoglycaemic events was also consistently lower with Gla-300 versus Gla-100, irrespec-
tive of concomitant DPPIVi use, both at night and at any time of day. This finding is consistent
with most other studies of combination therapy with basal insulin and DPPIVi, which have
reported no increased risk of hypoglycaemia in participants who received a DPPIVi plus insu-
lin compared with those who received insulin alone [8, 10]. In the analysis presented here, the
magnitude of the lower risk of hypoglycaemia for Gla-300 versus Gla-100 was generally consis-
tent whether DDPIVi therapy was present or not, although this lower risk for Gla-300 did not
achieve statistical significance in the ‘with DDPIVi’ group, most likely due to smaller sample
size and lower power than in the ‘without DPPIVi’ group. The lower number of participants in
the ‘with DPPIVi’ subgroup, and hence the lower number of confirmed (3.9 mmol/L [70
mg/dL]) or severe hypoglycaemic events (Gla-300: 446 events for ‘with DPPIVi’ vs 3523 events
for ‘without DPPIVi’; Gla-100: 807 events for ‘with DPPIVi’ vs 4390 for ‘without DPPIVi’),
made it more difficult to observe significant differences between treatment groups.
Results from this analysis indicate that the concomitant use of DPPIVi therapy had a gener-
ally neutral effect on body weight change, with a small increase in body weight (0.3–0.8 kg)
observed in all subgroups over 6 months of treatment. This is consistent with observations
from previous studies of the co-administration of a DPPIVi and insulin [8–10]. The adverse
event profile was generally similar between treatment groups and DPPIVi subgroups.
The limitations of this analysis are inherent to the post hoc nature. It should also be noted
that the EDITION studies were not designed to address the question posed by this analysis;
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however, they were designed from the outset to allow data to be pooled for post hoc analyses.
There were minor differences between the inclusion criteria in terms of HbA1c between EDI-
TION 2 (53 to86 mmol/mol [7.0 to10.0%]) and EDITION 3 (53 to97 mmol/mol
[7.0 to11.0]). To address this, the model used to analyse HbA1c change was adjusted on
the baseline HbA1c value. Moreover, participants from both studies had the same background
antihyperglycaemic treatments. As mentioned above, the differences in the number of people
in the DPPIVi subgroups may have limited data interpretation. Nevertheless, observations
from this analysis may help guide combination treatment in people with type 2 diabetes who
are on DPPIVi plus basal insulin therapy.
In conclusion, the comparable glycaemic control with lower hypoglycaemia risk with Gla-
300 versus Gla-100 was observed irrespective of concomitant DPPIVi use in this population of
people with type 2 diabetes. People with uncontrolled type 2 diabetes receiving a DPPIVi and
basal insulin may benefit from Gla-300 therapy.
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